Cargando…
Tedizolid vs Linezolid for the Treatment of Nontuberculous Mycobacteria Infections in Solid Organ Transplant Recipients
BACKGROUND: Treatment options for nontuberculous mycobacteria (NTM) infections are limited by the pathogen’s intrinsic resistance profile and toxicities. Tedizolid and linezolid display in vitro activity against NTM species. However, safety data and treatment outcomes are limited in the solid organ...
Autores principales: | Poon, Yi Kee, La Hoz, Ricardo M, Hynan, Linda S, Sanders, James, Monogue, Marguerite L |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8047851/ https://www.ncbi.nlm.nih.gov/pubmed/33884276 http://dx.doi.org/10.1093/ofid/ofab093 |
Ejemplares similares
-
1096. Linezolid versus Tedizolid for the Treatment of Nontuberculous Mycobacteria in Solid Organ Transplant Recipients: An Assessment of Safety
por: Poon, Yi Kee, et al.
Publicado: (2020) -
1083. Clinical Efficacy of Tedizolid for the Treatment of Mycobacterium abscessus complex Infections in Solid Organ Transplant Recipients
por: Poon, Yi Kee, et al.
Publicado: (2020) -
A Patient With Mycobacteremia Due to Two Different Nontuberculous Mycobacteria
por: Hill, Eddie, et al.
Publicado: (2022) -
In vitro Susceptibility of Nontuberculous Mycobacteria to Tedizolid
por: Zhang, Huiyun, et al.
Publicado: (2022) -
Treatment Dilemmas in Disseminated Nontuberculous Mycobacterial Infections With Interferon-gamma Autoantibodies
por: King, Elizabeth M, et al.
Publicado: (2021)